Lyell Immunopharma Ownership | Who Owns Lyell Immunopharma?

Lyell Immunopharma Ownership Summary

Lyell Immunopharma is owned by 57.08% institutional investors, 13.72% insiders, and 29.20% retail investors. Mwg management is the largest institutional shareholder, holding 7.87% of LYEL shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 1.91% of its assets in Lyell Immunopharma shares.

LYEL Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Lyell Immunopharma	57.08%	13.72%	29.20%
Sector	Healthcare Stocks	57.39%	9.93%	32.68%
Industry	Biotech Stocks	68.48%	9.65%	21.87%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Mwg management	20.16M	7.87%	$12.90M
Orland properties	15.09M	5.89%	$9.66M
Blackrock	13.50M	5.31%	$19.57M
Blackrock funding, inc. /de	13.27M	5.18%	$8.49M
Decheng capital	11.91M	4.65%	$7.62M
Vanguard group	9.77M	3.81%	$6.25M
Foresite capital management iv	8.32M	3.25%	$5.33M
Foresite capital management v	8.13M	3.17%	$5.21M
Wuxi apptec	7.68M	3.02%	$11.14M
Venbio partners	7.10M	2.77%	$4.55M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Wuxi apptec	7.68M	47.74%	$11.14M
Mwg management	20.16M	17.35%	$12.90M
Orland properties	15.09M	14.08%	$9.66M
Foresite capital management iv	8.32M	4.90%	$5.33M
Foresite capital management v	8.13M	4.33%	$5.21M
Venbio partners	7.10M	2.66%	$4.55M
Takeda pharmaceutical	823.32K	1.98%	$526.92K
Decheng capital	11.91M	1.63%	$7.62M
Alphabet	5.87M	0.22%	$3.75M
Mic capital management uk llp	1.74M	0.16%	$1.11M

Top Buyers

Holder	Shares	% Assets	Change
Decheng capital	11.91M	1.63%	11.91M
Foresite capital management v	8.13M	4.33%	8.13M
Venbio partners	7.10M	2.66%	7.10M
Renaissance	1.61M	0.00%	1.41M
Almitas capital	1.05M	0.15%	1.05M

Top Sellers

Holder	Shares	% Assets	Change
Orbimed advisors	3.10M	0.04%	-2.98M
Opaleye management	-	-	-1.40M
Balyasny asset management	-	-	-1.20M
Fmr	16.09K	-	-1.01M
Invenomic capital management lp	-	-	-871.52K

New Positions

Holder	Shares	% Assets	Change	Value
Decheng capital	11.91M	1.63%	11.91M	$7.62M
Foresite capital management v	8.13M	4.33%	8.13M	$5.21M
Venbio partners	7.10M	2.66%	7.10M	$4.55M
Almitas capital	1.05M	0.15%	1.05M	$672.33K
Takeda pharmaceutical	823.32K	1.98%	823.32K	$526.92K

Sold Out

Holder	Change
Nelson, van denburg & campbell wealth management group	-34.00
Rothschild investment	-50.00
Srs capital advisors	-95.00
Riggs asset managment	-150.00
Capital performance advisors llp	-171.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Dec 31, 2024	97	-17.09%	146,305,210	13.92%	57	2.27%	47	-6.00%	24	-22.58%
Sep 30, 2024	117	0.86%	128,424,945	-3.67%	50	1.82%	51	4.08%	31	-27.91%
Jun 30, 2024	116	-5.69%	133,324,052	0.44%	52	1.91%	49	-14.04%	43	-2.27%
Mar 31, 2024	123	5.13%	132,733,881	1.13%	52	1.92%	57	-1.72%	44	46.67%
Dec 31, 2023	117	12.50%	131,255,797	7.18%	52	2.18%	58	-4.92%	30	42.86%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
Vanguard Total Stock Mkt Idx Inv	5.64M	1.91%	-
T. Rowe Price Health Sciences	4.58M	1.55%	-69.15K
iShares Russell 2000 ETF	4.37M	1.48%	-37.84K
Biotech Growth Ord	2.88M	0.99%	-
Vanguard Small Cap Index	2.24M	0.87%	5.37K
Vanguard Institutional Extnd Mkt Idx Tr	2.52M	0.85%	-
Fidelity Small Cap Index	1.63M	0.55%	-30.59K
iShares Russell 2000 Value ETF	1.49M	0.51%	-
Vanguard Small Cap Growth Index Inv	1.25M	0.49%	-5.54K
State St Russell Sm/Mid Cp® Indx NL Cl C	1.18M	0.40%	-

Recent Insider Transactions

Date	Name	Role	Activity	Value
Mar 31, 2025	BRAWLEY OTIS W	-	Buy	$19.96K
Mar 21, 2025	Ramachandra Sumant	-	Buy	$115.22K
Mar 14, 2025	Klausner Richard	-	Buy	$94.94K
Mar 17, 2025	Newton Charles W.	Chief Financial Officer	Buy	$111.62K
Mar 14, 2025	Seely Lynn	President and CEO	Buy	$106.19K

Insider Transactions Trends

Date	Buy	Sell
2025 Q1	5	-
2024 Q4	-	-
2023 Q4	-	-
2023 Q3	-	1
2023 Q2	-	-

LYEL Ownership FAQ

Who Owns Lyell Immunopharma?

Lyell Immunopharma shareholders are primarily institutional investors at 57.08%, followed by 13.72% insiders and 29.20% retail investors. The average institutional ownership in Lyell Immunopharma's industry, Biotech Stocks , is 68.48%, which Lyell Immunopharma falls below.

Who owns the most shares of Lyell Immunopharma?

Lyell Immunopharma’s largest shareholders are Mwg management (20.16M shares, 7.87%), Orland properties (15.09M shares, 5.89%), and Blackrock (13.5M shares, 5.31%). Together, they hold 19.06% of Lyell Immunopharma’s total shares outstanding.

Does Blackrock own Lyell Immunopharma?

Yes, BlackRock owns 5.31% of Lyell Immunopharma, totaling 13.5M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 19.57M$. In the last quarter, BlackRock decreased its holdings by -397K shares, a -2.86% change.

Who is Lyell Immunopharma’s biggest shareholder by percentage of total assets invested?

Wuxi apptec is Lyell Immunopharma’s biggest shareholder by percentage of total assets invested, with 47.74% of its assets in 7.68M Lyell Immunopharma shares, valued at 11.14M$.

Who is the top mutual fund holder of Lyell Immunopharma shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of Lyell Immunopharma shares, with 1.91% of its total shares outstanding invested in 5.64M Lyell Immunopharma shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools